However, as baseline BDNF expression is substantially downregulated at both the mRNA and protein levels in the hippocampus of patients with DS, the downstream TrkB signaling pathway is also likely to be compromised in patients with DS, thus highlighting the translational significance of developing a BDNF-mimetic strategy for the treatment of the disease. This evidence concerns the gene NTRK2 and Dravet syndrome.